Ligand Pharmaceuticals Incorporated
Find Ratings ReportsLIGAND PHARMACEUTICAL INC's gross profit margin for the fourth quarter of its fiscal year 2023 has significantly increased when compared to the same period a year ago. Even though sales decreased, the net income has increased. LIGAND PHARMACEUTICAL INC is extremely liquid. Currently, the Quick Ratio is 12.49 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.
During the same period, stockholders' equity ("net worth") has increased by 17.31% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
Income Statement | Q4 FY23 | Q4 FY22 |
---|---|---|
Net Sales ($mil) | 28.1 | 50.38 |
EBITDA ($mil) | 5.35 | -2.63 |
EBIT ($mil) | -3.57 | -10.3 |
Net Income ($mil) | 18.19 | -17.49 |
Balance Sheet | Q4 FY23 | Q4 FY22 |
---|---|---|
Cash & Equiv. ($mil) | 170.31 | 211.87 |
Total Assets ($mil) | 787.22 | 762.67 |
Total Debt ($mil) | 6.18 | 87.75 |
Equity ($mil) | 700.91 | 597.49 |
Profitability | Q4 FY23 | Q4 FY22 |
---|---|---|
Gross Profit Margin | 96.22 | 74.83 |
EBITDA Margin | 19.03 | -5.21 |
Operating Margin | -12.7 | -20.44 |
Sales Turnover | 0.17 | 0.26 |
Return on Assets | 6.62 | -4.37 |
Return on Equity | 7.68 | -0.87 |
Debt | Q4 FY23 | Q4 FY22 |
---|---|---|
Current Ratio | 14.15 | 2.67 |
Debt/Capital | 0.01 | 0.13 |
Interest Expense | 0.13 | 0.24 |
Interest Coverage | -27.24 | -42.91 |
Share Data | Q4 FY23 | Q4 FY22 |
---|---|---|
Shares outstanding (mil) | 17.56 | 16.95 |
Div / share | 0.0 | 0.0 |
EPS | 1.03 | -0.86 |
Book value / share | 39.92 | 35.25 |
Institutional Own % | n/a | n/a |
Avg Daily Volume | 143830.0 | 106183.0 |
HOLD. The current P/E ratio indicates a significant discount compared to an average of 85.83 for the Chemical Manufacturing subsector and a discount compared to the S&P 500 average of 27.95. For additional comparison, its price-to-book ratio of 1.80 indicates a significant discount versus the S&P 500 average of 4.68 and a significant discount versus the subsector average of 19.07. The price-to-sales ratio is well above the S&P 500 average, but well below the subsector average. Upon assessment of these and other key valuation criteria, LIGAND PHARMACEUTICAL INC proves to trade at a discount to investment alternatives.
Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
LGND 23.98 | Peers 85.83 | LGND 25.47 | Peers 38.76 | |||||||||||||||||||||
Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations. LGND is trading at a significant discount to its peers. |
Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. LGND is trading at a significant discount to its peers. |
|||||||||||||||||||||||
Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
LGND 13.08 | Peers 18.08 | LGND 0.51 | Peers 1.16 | |||||||||||||||||||||
Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations. LGND is trading at a discount to its peers. |
Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. LGND trades at a significant discount to its peers. |
|||||||||||||||||||||||
Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
LGND 1.80 | Peers 19.07 | LGND 1037.50 | Peers 12.58 | |||||||||||||||||||||
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. LGND is trading at a significant discount to its peers. |
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. LGND is expected to have an earnings growth rate that significantly exceeds its peers. |
|||||||||||||||||||||||
Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
LGND 9.62 | Peers 84.44 | LGND -33.09 | Peers 42.35 | |||||||||||||||||||||
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. LGND is trading at a significant discount to its subsector on this measurement. |
Lower. A sales growth rate that trails the subsector implies that a company is losing market share. LGND significantly trails its peers on the basis of sales growth. |
|||||||||||||||||||||||